How does this company make money?
The company earns money in three ways. First, it sells Fluke electrical instruments and Sterrad sterilization systems as hardware — each unit sold generates a one-time payment. Second, and more steadily, hospitals must buy Sterrad hydrogen peroxide consumable cartridges every time they run a sterilization cycle, so each installed Sterrad system generates ongoing cartridge purchases tied directly to operating room activity. Third, Fluke customers pay for calibration services either on an annual contract or each time a service event occurs, because regulators require periodic recalibration to keep the instruments valid for compliance use.
What makes this company hard to replace?
A hospital that wants to move away from Sterrad must revalidate its entire sterile processing program — every instrument category, every cycle parameter — because the FDA cleared the existing process as a single closed system including the specific hydrogen peroxide formulation. That revalidation takes months and disrupts operating room throughput while it is underway. On the Fluke side, once a specific instrument model is written into a calibration procedure or a pharmaceutical process validation protocol that a regulator has already reviewed, changing to a different brand means requalifying the measurement method with that regulatory body, which is a formal process — not a simple equipment swap.
What limits this company?
Fluke can manufacture instruments relatively quickly, but it cannot serve a new country or region until there is a temperature-controlled, ISO 17025 accredited calibration laboratory in that area staffed with certified technicians. Without that laboratory, customers in that region cannot get the NIST-traceable recalibration their regulators require. Building that infrastructure takes time and money in every new market, and that requirement — not how fast instruments can be made — is what slows geographic expansion.
What does this company depend on?
The company cannot operate without NIST-traceable reference standards for calibrating Fluke instruments, FDA 510(k) clearances that authorize Sterrad sterilization systems to be used in hospitals, a functioning supply chain for the proprietary hydrogen peroxide concentrate that powers Sterrad consumables, ISO 17025 accredited calibration laboratories that perform recalibration services, and semiconductor components that go into Fluke electrical measurement circuits.
Who depends on this company?
Hospital sterile processing departments rely on Sterrad systems to turn over surgical instruments between operations — without those systems running, operating room schedules would slow or stop. Electrical technicians in factories depend on Fluke instruments to meet OSHA electrical safety rules; without accurate Fluke readings, their compliance records fall apart. Pharmaceutical manufacturing facilities use calibrated Fluke instruments as part of the documentation required to release drug batches — if those instruments were gone, batch release would stall.
How does this company scale?
The software features and measurement algorithms inside Fluke instruments can be copied across new units at almost no extra cost per device. What does not scale cheaply is the calibration service network — every new geographic market needs its own certified, temperature-controlled metrology laboratory and trained technicians before customers in that region can legally use the instruments for regulated work.
What external forces can significantly affect this company?
FDA regulations requiring hospitals to validate their sterile processing programs drive when and how hospitals buy or upgrade Sterrad systems, so regulatory changes at the FDA directly affect demand cycles. OSHA electrical safety standards in industrial workplaces require calibrated test equipment, which sustains Fluke's installed base but also means any weakening of those standards could reduce urgency to recalibrate. Export control restrictions on advanced measurement technology limit which countries Fluke instruments can be sold into, capping international expansion in certain jurisdictions regardless of local demand.
Where is this company structurally vulnerable?
If the supply chain for the proprietary hydrogen peroxide concentrate cartridges failed and no alternative formulation existed within the existing FDA clearance, hospitals would have no legal path to substitute a different consumable — doing so would trigger complete sterile processing revalidation. The same regulatory lock-in that keeps hospitals from switching to a competitor would also prevent them from finding a quick workaround, halting sterilization capacity until a new FDA clearance could be obtained.
CompanyGraph